Treatment of Sleep Apnea to Improve Metabolic Health
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUppsala University
About this trial
Diabetes and prediabetes prevail among obstructive sleep apnea (OSA) patients. OSA and short sleep both detrimentally affect glycemic control regardless of obesity. With 1 in 10 adults having diabetes, 1 in 10 with prediabetes, and an estimated 600,000 affected by OSA in Sweden, attaining glycemic control is crucial. Though continuous positive airway pressure (CPAP) is the most effective treatment for OSA, its application lacks personalization, ignoring factors like comorbidities and sleep duration. Key unanswered questions regarding CPAP's impact on glycemic control include: 1) Does high CPAP adherence optimize glycemic control? 2) Should short sleep be addressed alongside OSA treatment for glycemic control? 3) Does long-term diabetes hinder CPAP's glycemic control efficacy? The purpose of this project is to enable precision health in CPAP treatment and producing a personalized treatment model for achieving glycemic control in patients with OSA, treated with CPAP. Taking advantage of a large unique patient cohort (600 patients followed over 18 months) with extensive and objective measures on CPAP adherence, OSA reduction, sleep duration, as well as information on comorbidities, anthropometric, lifestyle data, and a wide range of biomarkers related to glycemic control. This comprehensive approach and in-depth analysis will address these questions and generate a personalized treatment strategy for glycemic control in CPAP-treated OSA patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients diagnosed with obstructive sleep apnea
Planned for CPAP treatment
18 years and above
Disqualifiers
Patient not wanting to participate in study
Non-Swedish speaking
Judged by physician as non-fit for study participation
Trial population
Patients with obstructive sleep apnea referred to the Sleep Apnea Unit at Uppsala University Hospital for CPAP treatment
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Homeostatic model assessment for insulin resistance (HOMA-IR)
Clinical marker: HOMA-IR calculated from blood glucose and serum insuling
Time frame
From enrollment to the end of treatment at 12 months2
Glycated hemoglobin (HbA1c)
Clinical maker: glycated hemoglobin (HbA1c) in % and mmol/mol
Time frame
From enrollment to the end of treatment at 12 months3
Blood glucose
Clinical marker: blood glucose in mmol/L
Time frame
From enrollment to the end of treatment at 12 months4
Serum insulin
Clinical marker: serum insulin in mU/L
Time frame
From enrollment to the end of treatment at 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Uppsala University
Lead sponsor
Uppsala University Hospital
Collaborator
Source ClinicalTrials.gov